Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 70 of 88 · 4178 articles
Nanoparticle technologies could eventually enable more targeted drug delivery and improved imaging for IBD and related GI diseases, which may lead to better diagnosis and less systemic side effects. However, translation...
This study identifies an immune pathway (IDO–AhR) that a parasite-derived antigen appears to activate to reduce experimental colitis in mice. That pathway is relevant because it helps explain how immune regulation might...
Measuring both how severe inflammation is and how much of the colon is affected could give a fuller picture of disease burden than current focal endoscopic scores. For patients with UC, that may affect risk assessment...
Surgical approach (open vs laparoscopic) affects recovery after ileocecal resection — shorter hospital stay and less bleeding with laparoscopy could matter for Crohn’s patients, especially where resources and access to...
The work models how Mycobacterium avium can provoke epithelial inflammation similar to Crohn's disease, pointing to possible molecular links between infection and CD-like pathology that could guide future research.
Researchers are exploring methods to make probiotic therapies more stable through the digestive tract and to deliver anti-inflammatory molecules directly where intestinal inflammation produces high reactive oxygen...
Gut microbes produce small molecules that interact with the host. This study shows lower levels of certain microbial aromatic carboxaldehydes (I3A and 4HBA) in feces from people with Crohn’s disease, suggesting a...
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
This review spotlights non-bacterial members of the gut microbiota (viruses and fungi) that may contribute to IBD by altering barrier function, immune responses, and interactions with bacteria. For people with IBD, these...
CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted...
The study describes new small molecules that target IL‑6 and NF‑κB and showed anti-inflammatory effects in laboratory and mouse colitis models, signaling a potential early-stage drug-discovery direction relevant to IBD...
This study shows a mechanism by which IL-10 protects gut epithelial mitochondria and barrier function during exposure to an IBD-associated E. coli strain, which could be relevant to understanding pathways that maintain...
Researchers are exploring microbiome-derived molecules as targeted, locally acting therapies for ulcerative colitis that might avoid systemic immunosuppression. EB1010 showed anti-inflammatory activity and...
The study suggests a new host-directed mechanism that helps a common beneficial gut bacterium (Faecalibacterium prausnitzii) colonize and protect the gut lining, and identifies heparan sulfate as a potential way to...
The review shows increasing research linking ferroptosis to autoimmune diseases including IBD and ulcerative colitis, which may guide future biomarker and therapy research relevant to people with Crohn's disease or other...
Autoinjectors can make long-term biologic treatment easier, more convenient, and potentially improve adherence for people with Crohn’s disease or ulcerative colitis who use ustekinumab.
This preclinical study suggests an herbal capsule formulation reduced colitis severity and shifted markers of oxidative stress, inflammation, and ferroptosis in mice — signaling possible biological pathways for future...
A blood biomarker that rises with active ulcerative colitis could help patients and clinicians monitor disease activity without relying solely on invasive tests. This study reports that serum type 23 collagen ectodomain...
This large, population-based study suggests people with Crohn's disease have modestly higher overall mortality than matched controls and higher deaths from specific causes (colorectal cancer, renal disease, non-Hodgkin...
The study highlights higher risks of tuberculosis and depression/anxiety associated with advanced therapies—especially anti-TNF agents—which are relevant safety concerns for people with IBD and their care teams. It may...
People using upadacitinib for Crohn’s disease or ulcerative colitis should be aware of a newly reported, reversible semen discoloration that may be dose-related. This could be concerning for patients and affect...
The study suggests that while Crohn's disease produces a shared dysbiotic signature at diagnosis, the specific microbes enriched differ by age — notably oral-associated taxa in children — which could affect research into...
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from Gut and liver.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
People with ulcerative colitis who have had colectomy can rarely develop inflammation of the small intestine and high-output stomas that are hard to control.
Researchers used machine learning to prioritize microbiome-related regulatory targets in Crohn's disease, which may guide future lab and clinical research into microbial pathways (like butyrate-related metabolism) that...
People with Crohn’s disease can have liver involvement that may be missed on routine exams. Quantitative liver MRI measures (fat fraction and extracellular volume) could help detect and monitor subtle liver injury...
If validated, the study points to a specific neutrophil subset that may drive inflammation and barrier damage in IBD, and to CXCR4 as a possible therapeutic target. That could open new biology-based treatment approaches...
Researchers used genetics, microbiome, metabolism, and immune profiling together to nominate biological pathways and a four-gene signature that might help diagnose or explain ulcerative colitis. If validated later, these...
The study links a common commensal fungus, Candida albicans, to a focused Th17 immune response that can turn harmful in Crohn’s disease, identifying a specific cell population that could be targeted more precisely than...
Energy depletion, poor sleep, and stress are common in Crohn’s disease and can worsen quality of life. Practical self-care strategies may help patients feel better day-to-day when used alongside medical treatment.
Low energy and fatigue are common in Crohn’s disease and can come from active inflammation, poor sleep, low appetite, or the emotional toll of a chronic illness. Practical lifestyle strategies may help patients feel...
If you have IBD — especially Crohn’s — this study suggests your long-term risk of needing dialysis or a kidney transplant may be higher than the general population. Certain treatments and prior bowel surgery were linked...
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Research and clinical...
Low BMI and visible undigested food suggest malabsorption, which can lead to malnutrition and serious health problems if not evaluated. The article emphasizes that this presentation warrants more than symptom-focused...
If validated, a blood biomarker (LRG) could help predict which people with Crohn’s disease are more likely to achieve remission and which biologic might be sustained over a year, informing treatment planning and...
People with UC have higher rates of low bone density, which raises fracture risk. This study links altered hormones (leptin, ghrelin, IGF‑1) and inflammation to lower BMD in UC, suggesting metabolic pathways that could...
Endometriosis involving the intestine can mimic Crohn’s disease symptoms and lead to misdiagnosis or delayed correct treatment. Patients with IBD-like symptoms who are of reproductive age may need evaluation for bowel...
The study targets oxidative stress and the TXNIP/NLRP3 inflammasome axis, both implicated in IBD inflammation and barrier damage. If translatable, nanozyme-assisted probiotic therapy could offer a novel, targeted way to...
A natural compound (C3G) reduced inflammation and changed gut bacteria and metabolites in an experimental colitis model, pointing to possible new mechanisms or leads for IBD therapies.
This trial tests whether raising the upadacitinib dose to 45 mg can recapture clinical response in people with ulcerative colitis who lost response on the 30 mg maintenance dose. If effective and safe, the approach could...
This trial tests palmitoylethanolamide (PEA), a commercially available supplement with anti-inflammatory actions, as an add-on treatment for mild-to-moderate ulcerative colitis.
This study suggests that higher intake of specific fibers (beta‑glucan and inulin) may be linked to lower Crohn’s risk in people with a family history, and it connects those fibers to biomarkers of inflammation, barrier...
Reports a rare mesenteric fibroinflammatory complication in a patient with UC who was in remission on vedolizumab, raising a hypothesis about possible associations worth further study.
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
GI perforation is a serious, potentially life-threatening complication that can occur in people with autoimmune diseases; this report highlights that perforation can happen during corticosteroid tapering and that careful...
The work identifies a genetic link (HLA‑DRB1*01:03) to anti‑IL‑10 autoantibodies and describes a small subgroup of IBD patients who may have a distinct immune mechanism driving disease—information that could matter for...
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...
